Alnylam and Collaborators Publish New Pre-clinical Results with an RNAi Therapeutic Approach for Inducing Endogenous Erythropoiesis for the Treatment of Anemia
08:00 EDT 12 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced the publication of new pre-clinical results in the
journal Blood
(doi: 10.1182/blood-2012-04-423715) that describe targeting the...
Other Sources for this Article
Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Vice
President, Investor Relations and
Corporate Communications
or
Spectrum
(Media)
Amanda Sellers, 202-955-6222 x2597
More From BioPortfolio on "Alnylam and Collaborators Publish New Pre-clinical Results with an RNAi Therapeutic Approach for Inducing Endogenous Erythropoiesis for the Treatment of Anemia"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
